TNFRSF9 and head and neck squamous cell carcinoma: We identified blood circulating CD137+Tregs and LOX-1+PMN-MDSCs as novel biomarkers associated with clinical outcomes, potentially useful for improving patient selection and the efficacy of immunotherapy in (R/M) HNSCC patients.